#For patients
Written for adults considering a peptide as part of their health management.
GLP-1 Drugs and Aesthetic Surgery
A 2026 narrative review maps aesthetic-surgery concerns after GLP-1-related weight loss but reports no new trial or proven drug-specific effect.
SURPASS-EARLY Tirzepatide Results
SURPASS-EARLY found larger two-year HbA1c and weight reductions with tirzepatide than flexible conventional care in early type 2 diabetes.
Weight Loss and Sleep Apnea: 2026 Review
A 2026 review links obesity treatment with better sleep-apnea measures. We separate its conclusions from the randomized tirzepatide evidence.
GLP-1 drugs and the ocular surface
A 2026 review links GLP-1 drugs to possible ocular-surface repair and changes around the eye, but human evidence remains small and observational.
GLP-1 drugs and sleep apnea outcomes
A matched US database study links GLP-1 drug use in sleep apnea with fewer strokes, hospital visits and deaths, but it cannot prove cause and effect.
GLP-1 skin reactions: what two cases show
Two case reports link GLP-1 medicines to unusual skin reactions. Here is what they observed, and why they cannot establish risk or causation.
Tirzepatide and muscle loss: what we know
Tirzepatide weight loss includes fat and lean mass changes. Here is what body composition research can, and cannot, tell you.
Tirzepatide vs semaglutide: indirect data
A 2026 analysis compared SURMOUNT-1 with STEP 1. Tirzepatide 10 mg and 15 mg were associated with greater weight reduction, but this was not a new trial.
Semaglutide in Pediatric Craniopharyngioma
A 20-patient retrospective series links semaglutide with lower BMI in adolescents with craniopharyngioma-related obesity, but cannot prove causation.
Tirzepatide lean-mass review
A 2026 review found that tirzepatide weight loss mostly came from fat, but lean mass also fell and muscle function was not measured.
Tirzepatide and NAION: New Record
A new French journal record names tirzepatide and NAION, but its no-abstract PubMed entry cannot establish clinical details or causation.
New amylin agonists for obesity and T2D
Zenagamtide, eloralintide and CagriSema have early to late-stage results in obesity and type 2 diabetes. Their evidence is not interchangeable.